The gold standard treatment for deep burns is an autologous skin graft; in larger burns this may be meshed to increase the area covered. However, long-term aesthetic and functional outcomes of graft scars may be poor. ReCell ® is a medical device that processes skin samples in the operating theatre into a cell suspension to be sprayed or dripped onto a wound. It is claimed to improve healing and scar appearance. This device was evaluated by the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme. Two groups were defined: ReCell compared to conventional dressings in shallower burns, and meshed grafts plus ReCell compared to meshed grafts alone in larger deeper burns. The manufacturer's clinical evidence submission included three papers and eight conference abstracts. The External Assessment Centre (EAC) excluded two of these and added seven abstracts. In general, the evidence did not fit the defined groups, but suggested that ReCell was clinically comparable to skin grafts for partial thickness burns; however, ReCell is not used in this way in the UK. The manufacturer submitted an economic model in which ReCell treatment of partial thickness burns reduced the requirement for later skin grafts. This indicated that ReCell alone was cost saving in comparison to conventional dressings. The EAC indicated that this model was clinically inappropriate, but data were not available to populate a new model. NICE Medical Technologies Guidance 21 recommended that additional research was needed to address the uncertainties regarding the potential benefits of ReCell.
Introduction
This is one of many articles in Applied Health Economics and Health Policy summarising guidance produced by the National Institute for Health and Care Excellence (NICE) Medical Technologies Evaluation Programme (MTEP). The MTEP process is explained in Campbell and Campbell [1] . This paper summarises the development of NICE Medical Technology Guidance for the ReCell Spray-On Skin system (Avita Medical Ltd) for treating burn injuries [2] . The External Assessment Centre (EAC) that produced the assessment report and additional survey work was Cedar (including Cardiff and Vale University Health Board, Cardiff University and Swansea University). The manufacturer of the product notified the technology to NICE.
Background

Burns
Thanks to effective prevention strategies and comprehensive emergency services, major burns are a relatively uncommon condition in most developed countries, including the UK [3] . Healing and scar outcomes are related to the length of time that a burn wound takes to heal; burns that will heal within 14 days are at low risk of poor outcomes [4, 5] . The aim of the acute phase of burn treatment is therefore to achieve wound healing within 10-14 days.
Skin burns and scalds are characterised by the extent and depth of the skin injury, commonly described as total burn surface area (TBSA) and expressed as a percentage of the total surface area of the patient. Burn depth indicates the deepest skin layer that has been damaged and can be expressed in a variety of ways: superficial, intermediate, deep, epidermal, dermal, partial thickness and full thickness.
Superficial/epidermal burns damage only the outer layer of the skin and these will heal well without significant specialist intervention. Full thickness burn injuries penetrate the entire thickness of the dermal layer and can involve subcutaneous tissues (fat, muscle and bone). These require skin grafts and may also involve the use of artificial dermal substrates/scaffolds. Burns that penetrate partly through the dermal layer may be treated with grafting or dressings, depending on the depth. Alternatively, the depth of a burn may not be easily determined by clinical examination. NICE has recommended that the moorLDI2 Burn Imager be used in such indeterminate depth cases to predict healing time and aid clinical decision making regarding treatment options [6] .
Autologous split thickness skin grafts are the 'gold standard' treatment for deep burns and those that are expected to take more than 10-14 days to heal. Injuries to areas of cosmetic or functional importance (e.g. face, hands and groin) are usually treated with sheet grafts. Small burns in other areas that require grafting may also be treated with sheet grafts or be minimally meshed or fenestrated to prevent fluid build-up and promote contouring. Where the patient has extensive wounds, and therefore less spared skin available to provide grafts, the mesh ratio may be increased to extend the area that the graft can cover. Meshing may also be used where skin sparing is important, e.g. in elderly patients who heal poorly. This has the disadvantage of poorer cosmetic outcomes (the mesh pattern may be visible in the healed scar) and contractures.
Organisation of Burn Care Services in England and Wales
Burn care services are a specialised clinical service in England and Wales [7] , organised into four regions and designated by three levels (separately for adult and paediatric patients). The level defines the maximum severity of burn injury treated: Facility (least severe), Unit and Centre (most severe injuries). Data from the National Burn Injury Database indicate that around 900 patients per year have injuries severe enough to warrant referral to a Burns Unit or Centre in the UK [8] .
Technology
The ReCell ® Spray-On Skin system is a kit for use in the operating theatre that enables immediate processing of a skin sample into a cell suspension for spraying or dripping onto the burn wound, mesh graft or donor site. It is a Class III medical device and obtained a CE mark in March 2005. It consists of a sterile tray incorporating a battery-operated timer and warming chamber, preparation area and other necessary consumables. The biopsy is incubated in a trypsin solution for 15-30 min to disaggregate the cells. These are mechanically scraped and drawn up in a buffer solution ready for use. Each unit can process a biopsy up to 4 cm 2 , which can treat an area of 320 cm 2 . The suspension contains a mixture of keratinocytes, melanocytes, Langerhans cells and fibroblasts. 
National Institute for Health and Care
Excellence Scope
The NICE scope for the ReCell evaluation defined two sets of populations, interventions and comparators.
Population, Intervention and Comparator
The populations, interventions and comparators of interest were divided into two subgroups and included adults or children treated in Burns Units or Centres (Table 1) .
Outcomes
The outcomes specified for consideration in the scope included speed of healing, number of dressings (with or without anaesthesia), length of hospital stay, wound infection rates, degree of scarring (aesthetic and functional outcomes), degree of pigmentation, re-admission for scar management, number and size of donor sites, surgical procedure or theatre time, and device-related adverse events. Evidence was also submitted regarding postoperative pain and analgesia use, graft 'take/loss' and rate of subsequent skin grafting (following conservative treatment with ReCell). No evidence was submitted regarding readmission, and pigmentation outcomes were included in overall measures of scar quality. 1 Avita Medical changed the specification of the ReCell device in 2015 and it can now process up to six 4 cm 2 samples to treat an area up to 1920 cm 2 .
Manufacturer's Claims
In their submission, the manufacturer claims the following patient benefits from the use of ReCell:
• a reduction in skin graft donor site size and depth;
• fewer complications, reduced morbidity and shorter healing time at the donor site; • shorter wound healing time at the recipient site, leading to:
• an improved burn wound aesthetic result with a lower likelihood of scarring and better match of skin colour; • re-population of melanocytes to reduce hypopigmentation in healed wounds;
• reduced dressing change frequency (weekly rather than daily); • less need for dressing changes under anaesthetic.
The claimed benefits to the healthcare system are reductions in:
• length of stay in hospital; weekly rather than daily dressing changes allowing earlier discharge and outpatient management, thus reducing the costs of care; • need for re-dressings under anaestheia, again reducing the costs of care; • requirement for external technical laboratory support; • likelihood of later readmission for corrective surgery as a result of improved aesthetic results.
Review of Clinical and Economic Evidence
The manufacturer submitted a review of clinical and cost evidence to NICE and presented a de novo cost-consequences model.
Manufacturer's Submission of Clinical Effectiveness Evidence
The manufacturer included 11 references in their clinical evidence submission, three peer-reviewed publications and eight conference abstracts, including one unpublished abstract that overlapped with Sen et al. [9] . The three papers included two randomised controlled trials [10, 11] and an observational study [12] . The conference abstracts included one service review, [13] two comparative studies [14, 15] and five case series [9,16-18, unpublished] . The EAC considered that two of the conference abstracts did not fit the scope; one used ReCell to treat donor sites [17] and the other to treat hypertrophic scarring [18] . Additionally, the manufacturer searched for pigmentation outcomes in any population, producing five studies in which ReCell had been used to treat established scars or stable vitiligo. The EAC considered that these studies were outside the scope. The studies identified by the manufacturer and included by the EAC are described in Table 2 .
Owing to the degree of heterogeneity in the populations, treatments and comparators in the published evidence, the manufacturer conducted a qualitative analysis of each study in their submitted clinical evidence. The only biological dressing reported in the clinical evidence was Biobrane (Smith and Nephew). This is a commonly used dressing in superficial and partial thickness wounds that adheres to the wound until healed.
The manufacturer's interpretation of the evidence stated that:
• ReCell was comparable to split thickness skin grafts (SSGs) for wound healing, scar outcome and infection risk in partial thickness burns; • the addition of ReCell to SSGs increased the rate of epithelialisation; • the use of ReCell with biological dressings was associated with faster healing, lower costs and shorter hospital stay than SSGs; 
Critique of Manufacturer's Submission of Clinical Evidence
The EAC literature search was broader than that conducted by the manufacturer. An additional nine conference papers were identified (Table 3) . Two were unobtainable and four others contained data that potentially overlapped with references identified by the manufacturer. Overall, the EAC included 11 or 12 studies reported in 15 papers. 2 Gravante et al. [10] conducted a randomised controlled trial comparing ReCell alone (n = 42) with an SSG (n = 40) in deep partial thickness burns of up to 320 cm 2 . The method of patient randomisation was unclear but the groups were matched for age, sex, burn type and TBSA. There was no difference between the treatment groups for burn treatment size, mean time to epithelialisation or aesthetic outcome at 6 months (using a simplified Vancouver Scar Scale). Donor site size was smaller in the ReCell group and post-operative pain was reduced; however, operation time was longer using ReCell. Healing assessment was by one blinded and one unblinded assessor at weekly intervals, thus the precision of the time to epithelialisation is likely to be poor. The study design also does not match the groups defined in the evaluation scope. Healing time and Vancouver Scar Scale were similar between the groups, indicating that ReCell alone has similar effect on the burn wound as an SSG alone. However, ReCell alone is not used on deep partial thickness burns in the UK.
Park et al. [12] conducted a retrospective, multivariate logistic regression analysis including all patients in a burn centre who required skin replacement from 2004 to 2011. Primary outcome was the risk of infection compared to an SSG alone. Of 770 eligible patients, 73 were treated with ReCell alone, 264 received ReCell plus an SSG and 387 received an SSG alone (48 patients were excluded overall, but final numbers in each group are not reported). There was no effect of treatment type on burn wound infection or graft loss. Length of stay was significantly reduced in the ReCell alone group (odds ratio 0.70, p < 0.01); however, the authors note that the patient groups were not strictly comparable as "practice indications (wound depth) and timing of surgery" were different. Interpretation of these results should be cautious. The co-inventor of ReCell and a non-executive director of Avita Medical is a co-author (F. Wood). Wood et al. [11] conducted a pilot study to determine whether early intervention could reduce the need for skin grafts. The three-arm randomised controlled trial compared ReCell plus Biobrane (n = 5), Biobrane alone (n = 4) and standard care (n = 4). The patient population was paediatric patients with a scald injury greater than 2% TBSA that was likely to benefit from surgery (not expected to heal within 10 days). Standard care patients received silver and hydrocolloid dressings on alternate days. Only 13 patients were enrolled in the study (45 were intended) so that only descriptive statistics or individual values were reported. In the standard care group, three of four patients received a skin graft at 10 days post-treatment, compared with zero of five in the ReCell plus Biobrane group and one of four in the Biobrane alone group. Healing appeared to be faster in the two intervention groups, although this may have been owing to complications in two of four patients allocated to standard care. Other outcomes are difficult to interpret and do not support comparative conclusions. There was a disparity between the treatment groups such that patients in the ReCell plus Biobrane group were younger and had smaller burn areas. This may have significantly impacted the outcomes. The patient population also does not match that in Group A of the scope. The low patient numbers and consequent lack of statistical power mean that conclusions cannot be drawn from this study regarding the benefits of ReCell. Again, the main author (F. Wood) has a conflict of interest in the product.
Multiple conference abstracts reported data from the same patients, and it was not always clear where overlap existed. Therefore, the total number of 'studies' is uncertain. There were three comparative studies ( [14, 19] ; [15, 24, 25] ; [27] ) and two service reviews, [13, 20] with potential for overlap with each other and with two of the comparative reviews. The rest were case series ( [9] , [16] and unpublished; [21] , [22] ).
Rawlins [14] and Dunne and Rawlins [19] reported a retrospective comparison between ReCell (n = 11) and SSGs (n = 15 in [14] ; n = 10 in [19] ) in deep dermal scalds in paediatric patients. There was no difference in scar appearance (visual analogue scale) between the groups, operation time was longer and physiotherapy duration was shorter in the ReCell treatment group. However, TBSA was greater in the ReCell group and no other information about the physiotherapy delivered or duration of follow-up was reported. No data other than TBSA were presented to allow baseline comparison of the groups. There was a suggestion of a blinded assessment of scar appearance, but there were disparities in the scar results reported in the two abstracts not attributable to the difference in the size of the control groups. The intervention does not match the defined scope groups and ReCell alone is not considered appropriate as an alternative for SSGs in the UK.
The second comparative study was reported in three conference abstracts [15, 24, 25] . Adults with deep dermal flame burns were recruited prospectively for treatment with ReCell plus Biobrane (n = 5 in [15] ; n = 4 in [24] and [25] ) and compared to matched controls who received SSGs (n = 10). Mean time to healing, analgesia requirements for the first dressing change and length of stay were lower, and scar assessment (Vancouver Scar Scale at 6 months) better, for the ReCell plus Biobrane group. However, there is no indication of the variance of any of the data or the statistical significance of the results and the use of means in such small samples may be misleading. No blinding of assessors was reported and the patient matching is poorly described. Again, the intervention does not match the scope groups and ReCell alone is not considered appropriate as an alternative for SSGs in the UK. Sood et al. [27] conducted an intra-patient comparison between ReCell alone and meshed SSG in partial thickness burns (n = 10). Only graft take is reported; eight of ten patients had a 100% take on both areas and two had a reduced take in the ReCell-treated area. These were attributed to difficulty with the ReCell applicator and increased wound depth. Little detail is provided.
The evidence available is mainly of poor quality and is not a good fit with the groups defined in the scope. However, taking the evidence as a whole, the EAC concurs with the manufacturer that ReCell appears to be at least as effective as SSGs for wound healing, scar outcome and infection risk in partial thickness burns. However, in the UK, cell therapies are not used as an alternative to SSGs, and evidence comparing SSGs with ReCell plus SSGs (as per the decision problem) was only available in Park et al. [12] . In the scope, the use of ReCell alone is only considered in Group A populations as an alternative to biological or standard dressings. The EAC found that there was no evidence to support the claim that the addition of ReCell to SSGs was associated with faster healing and better scar outcomes, and that there were minimal indications for any system benefits (reduced length of stay and frequency of dressing changes). The EAC also concluded that there was no evidence to indicate that the use of ReCell as an adjunct to Biobrane conferred any additional benefit over Biobrane alone.
Additional Work Carried out by the External Assessment Centre
The available evidence was highly heterogeneous and did not correspond to the scope. The groups in the scope were somewhat ambiguous and were redefined by the EAC:
• Group A: partial thickness burns or scalds where skin grafting (meshed or unmeshed) is not required. • Group B: full thickness or deep partial thickness burns where skin grafting (including meshed grafting in larger burns) is required.
The EAC categorised the included studies according to these groups (Table 4) . Wood et al. [11] described their patient population as partial thickness scalds but these were expected to benefit from surgery and do not strictly fit with the Group A definition. However, the intervention and comparator match with those of the Group A population, thus this study was categorised as Group A. Only Park et al. [12] are completely consistent with the groups; however, the authors note that the populations and treatments were not directly comparable in their retrospective analysis.
Manufacturer's Economic Submission
The manufacturer included eight published studies and one unpublished audit in their economic submission. None of the evidence related to ReCell, but was used to identify cost data for the standard care comparator. The manufacturer did not include Wood et al. [11] which contained some cost data relating to their three-arm, randomised controlled pilot study. The economic evidence was supplied as a de novo cost model, implemented in TreeAge Pro (TreeAge Software, Inc., Williamstown, MA, USA).
The manufacturer only modelled Group A from the scope, stating that there was insufficient evidence available to model Group B. The model was a simple decision tree, comparing four treatment options: ReCell plus conventional dressings, ReCell plus Biobrane, Biobrane alone and conventional dressings alone. They used published evidence and information from a questionnaire sent to four burns surgeons who had experience of using ReCell. Three of these were (or had been) based in the UK, of which two were also acting as expert advisers to the NICE evaluation. The fourth was a co-inventor of ReCell and a non-executive director of Avita, based in Australia.
The model base case was a 640 cm 2 partial thickness burn, surgically debrided and treated according to one of the four options above under general anaesthesia. Patients were then treated as either inpatients or outpatients. A change of dressings was defined as major (conventional dressings) or minor (Biobrane and/or ReCell) and occurred at intervals dependent on the treatment type. At 10 days post-treatment, a decision to progress to a skin graft is taken. Following a skin graft, the wound is assumed to heal within a further 10 days. Otherwise, the patient is assumed to be healed at 15 days for a conventional dressing (base case) and a proportionate reduction of this time is used for the other three treatment types. The time frame of the model was the acute treatment of the burn wound. The structure is identical for all four treatment sub-trees, thus only part of the model is shown in Fig. 1 . Probabilities and resource inputs are shown in Tables 5 and 6 .
The base-case results for the economic model are shown in Table 7 . The manufacturer calculated that ReCell and ReCell plus Biobrane were both cost saving in comparison to conventional dressings, but that Biobrane was the lowest cost treatment overall. Cost savings for ReCell treatments are driven by the lower proportion of patients requiring an SSG and the shorter healing time. Incremental Biobrane savings were driven by the lower technology costs compared with ReCell for similar outcomes.
Because of the significant uncertainty in the model parameters, the manufacturer conducted one-way sensitivity analyses using broad ranges of values for each parameter. Although the total payoffs varied, the relative cost ranking of the treatments did not. The manufacturer also conducted scenario analyses, varying the burn size by ± 50%, all hospital costs by ± 25% and reducing all benefits by 50%. ReCell and ReCell plus Biobrane remained cost saving with respect to conventional dressings for all scenarios except the reduced burn size (TBSA of 320 cm 2 ); however, Biobrane remained the cheapest treatment in all scenarios. [13] Mid-deep dermal scalds B ReCell + Biobrane A NA Dunne and Rawlins [20] Mid-deep dermal burns B ReCell + Biobrane A NA Echlin [16] Mid-deep dermal burns B ReCell A NA Fig. 1 Tree diagram for the manufacturer's economic model (part). pInpatient probability of being treated as an in-patient, pSSG probability of requiring a split thickness dermal graft after 10 days, # indicates residual (complementary) probability
Critique and Interpretation of Cost Evidence
The manufacturer did not attempt to model the Group B population, intervention and comparator and did not include long-term outcomes. There was a poor fit between the available evidence and the defined groups and the longest followup in any of the included studies was 6 months. No data were identified for the effect on scar treatments or duration of rehabilitation. The model was robust to the sensitivity and scenario analysis regarding the relative cost-ranking outcomes. Most of the parameters used for the model were based on weak or poorly described evidence and this rendered these outcomes doubtful. The manufacturer used an unpublished audit of burns patients in a UK burns service for all the resource costs used in the model with the exception of list prices for Biobrane and ReCell. These data were available to the EAC as a spreadsheet but lacked descriptions of how the data were collected and specifically how cost information was obtained.
The manufacturer also used data from the questionnaire in which the manufacturer described the patient population as '5-10% partial thickness burns of indeterminate depth'. This is not fully consistent with the Group A patient population nor with the description of the population given in the model ('partial thickness burns or scalds, where there is no immediate need for mesh grafting' and 'partial thickness with no definite areas of deep involvement'). The experts answered the questions in a variety of ways, making interpretation and aggregation of the data very difficult.
Healing times (time to complete epithelialisation) for conventional dressings were drawn from published studies comparing different dressing types in heterogeneous burn injuries. The EAC considered the value for the base case (15 days) to be appropriate when compared to other available data. The percentage reduction in healing times for the three other treatments (see Table 5 ) are partly based on calculations using outcomes from Wood et al. [11] and Echlin et al. [17] . Wood et al. [11] had only four to five patients for each arm and did not include ReCell alone. Echlin et al. [17] was an intra-patient comparison of graft donor sites in two patients using ReCell alone vs. conventional dressings. The manufacturer recognised the paucity of evidence and described the 30% and 40% reductions in healing time as a 'conservative estimate'. The one-way sensitivity analysis varied this percentage reduction from 0 to 50% of the base-case value (7.5-15 days). The EAC considered that a percentage reduction in healing time was inappropriate; however, the range of values tested in the one-way sensitivity analysis was broad and included parity with the other treatment arms. The manufacturer provided an extra 10 min of theatre time for the use of ReCell. Published data reported that ReCell requires an additional 28-39 min of theatre time in comparison to SSGs [10, 14] . The EAC considered that 10 min may be an underestimate in comparison to treatment with conventional dressings, where only debridement and dressings are conducted in theatre in the model. As theatre time is estimated at £5214 per hour, this may have a significant effect on the relative cost rankings.
Estimates of the proportion of patients needing SSGs after 10 days were much lower from two experts (up to 10% of patients) than that used by the manufacturer. The manufacturer's estimate of 30% for conventional dressings comes from several papers comparing different topical treatments but includes heterogeneous patient populations. The information from the clinical experts suggested a reduction in the proportion of patients requiring SSGs for the other three treatment types, but there was no overall consensus. The manufacturer used a broad range of values for the one-way sensitivity analysis (5-20%); this was increased by the EAC for the ReCell treatments to include parity with conventional dressings.
The proportion of patients who require inpatient treatment following surgery is dependent primarily on the patient's pain level and the site and extent of the burn. However, there are non-clinical reasons for patients to remain on a burn ward rather than be discharged to outpatient care. Despite confusing information from the questionnaire, it seemed that most patients with injuries consistent with the modelled population would be discharged following the first dressing change on days 2-3 post-procedure. The manufacturer used an 'arbitrary' estimate of 50% for conventional dressings and 25% for all other treatment types. There was no evidence that ReCell alone reduces the need to remain as an inpatient. The manufacturer's reasoning appeared to be based on a clinical adviser comment that conventional dressing changes ("major change of dressing") are more likely to require morphine anaesthesia and therefore inpatient treatment than the other treatment types ("minor/secondary dressings only"). The manufacturer used a range of 25-75% for all treatment arms in their sensitivity analysis. Biobrane adheres to the wound and remains until it lifts off as the wound heals. The EAC therefore expects that the use of Biobrane can reduce the complexity, pain, time and cost of dressing changes. This may reduce the need to remain as an inpatient for treatment arms that include this product.
In the manufacturer's model, any patient being treated as an inpatient following the first dressing change remained as an inpatient until the burn was healed or required an SSG. This is inappropriate, as patients who are healing well are likely to be discharged as soon as reasonably possible. As daily bed and staff costs are £621, this could contribute to the differences in cost outcomes for each treatment.
The Medical Technologies Advisory Committee (MTAC) accepted that assumptions and parameters used in the manufacturer's model were of uncertain validity and noted the lack of modelling of the Group B patient population. The committee requested that the EAC conduct additional work to obtain data from clinical experts to validate the manufacturer's model and to provide an economic model for largearea full or deep partial thickness burns.
Additional Economic Analysis Conducted by the External Assessment Centre
The EAC extended the ranges of the inputs for the sensitivity analysis for the proportion of patients progressing to an SSG and the cost of a change of dressing (both major and minor). The model remained robust to one-way analyses and the cost rankings of the treatment arms did not alter. The EAC conducted a literature search to identify current UK clinical practice and suitable parameters for use in the additional modelling. This information and the assistance of two clinical expert advisers were used to develop a questionnaire survey for UK burns specialists. The aim was to obtain detailed information regarding the treatment of different categories of burn injuries. The questionnaire included the current standard treatment and participants' experience with both ReCell and cultured autologous cells. Participants were interviewed by telephone by the main author (SCP) and the data tabulated and aggregated.
Information was obtained from nine consultant burn surgeons and one specialist burns nurse from a mixture of UK adult and paediatric Burn Units and Centres during February 2014. Of these, seven had direct experience of using ReCell. Specialists were unable to provide quantitative estimates with which an economic model could be populated. As a result, no additional economic modelling could be conducted.
There was significant variation in treatment protocols between sites/clinicians; however, a consensus was reached on several important points:
• Shallower partial thickness burns, such as those described in the Group A patient population, will heal within 2 weeks without special treatment. For adults, these injuries are usually treated on the ward using conventional dressings. Most clinicians would not use ReCell on these patients and in general Biobrane would only be used in paediatric patients. Length of stay is typically 4-6 days.
Neither ReCell nor Biobrane was thought to contribute to faster healing. • A 10% TBSA full thickness or deep partial thickness burn is likely to be treated using a sheet graft and ReCell would not be used in conjunction with this. Where a meshed graft is used, no effect of ReCell on any parameters (other than theatre time) was identified.
• Large burns (around 40% TBSA) requiring meshed grafts are rare events, are highly individual and complex, and data are difficult to aggregate. This is the group of patients most likely to receive either ReCell or cultured cell treatments in the hope of reducing healing time and improving aesthetic appearance. Length of stay for these patients is complicated by multiple factors. ReCell is advantageous when cultured cells are unavailable and to take advantage of unused donor graft skin.
• No evidence was found to support the claim that ReCell improves long-term scar outcomes. Specifically regarding pigmentation outcomes, both expert opinion and additional published comparative studies (in which ReCell was used as a treatment for re-pigmentation of vitiligo) were equivocal.
The EAC found no evidence that claims of a clinical or system benefit from the use of the ReCell Spray-On Skin system had been realised in current UK practice. The survey indicates that the manufacturer's model was inappropriate, but no additional data were obtained with which to populate a more realistic model.
National Institute for Health and Care
Excellence Guidance
Preliminary Guidance
The NICE MTAC met in March 2014 and considered evidence from a range of sources, including the manufacturer's submission, the EAC assessment report, expert survey and testimony from clinical experts. The committee provisionally decided that the ReCell Spray-On Skin system shows potential to improve healing in acute burns and that research is recommended to address uncertainties about the claimed patient and system benefits of the ReCell Spray-On Skin system.
Consultation Response
Preliminary guidance was available for public consultation between 16 April and 19 May, 2014. The manufacturer made several comments and provided additional evidence that had become available since the original submission. The EAC examined the additional evidence and concluded that it did not change the previous conclusions on the evidence. NICE published Medical Technology Guidance on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury on 12 November, 2014 as MTG 21 [2] .
Key Challenges and Learning Points
• Burn injuries are difficult to categorise and patients are likely to have a range of burn depths and therefore represent a continuum of injury severity.
• Study data are often presented at multiple conferences with overlapping or wholly reproduced patient samples without reference to previous publications.
• Studies from outside the UK may not represent UK practice and therefore be of limited applicability.
• Despite best efforts, the scope may not reflect the most appropriate technology application.
• Data for long-term outcomes are often not available, limiting the usefulness of economic modelling.
